Last updated on March 2019

A 12-week randomized, double-blind, parallel-group, placebo-controlled study to determine the efficacy and safety of biphasic remogliflozin etabonate when administered to subjects with type 2 diabetes mellitus.

Other Details:

Oral treatment to blood sugars, potential weight loss from medication, class of drugs is already approved and this medication should have less side effects

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.